LONDON (Reuters Health) – AstraZeneca said on Friday that it had launched its fast-acting migraine nasal spray Zomig (zolmitriptan) in Sweden at a price marginally cheaper than GlaxoSmithKline's rival sumatriptan spray formulation.
Global product manager Garry Megson said that the Swedish price is 83.50 Krone for a pack of 18, 5mg sprays, 3 Krone less than the sumatriptan spray, but at a premium to existing Zomig tablets, which are priced at 50 to 57 Krone.
The new spray formulation, which the firm says starts working within 15 minutes, was reviewed by the European Medicines Evaluation Agency, with Sweden acting as the reference member state.
Megson told Reuters Health that it would be rolled out in other European markets in the second half of 2002, followed by the United States in 2003.
He said that AstraZeneca is the only company to offer a triptan migraine remedy in tablet, rapid-melt, and nasal spray form, and forecast sales would rise from nearly $300 million last year to $500 million by 2004, a quarter of the global market.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!